16 completed, 11 recruiting, 2 not yet recruiting, 2 terminated. 34 Phase 1, 12 Phase 2.
Follow Malignant Neoplasm: new trials by email Literature Review of Malignant Neoplasm trials Research Report on Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 300 | 2026-11-16 | 2026-10-15 |
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Ifinatamab Deruxtecan - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 134 | 2026-07-06 | 2026-10-30 |
| A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) Pembrolizumab - Malignant Neoplasm, Carcinoma, Merkel Cell | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 20 | 2026-06-23 | 2026-07-13 |
| Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) MK-4884 - Malignant Neoplasm | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 120 | 2026-06-18 | 2026-10-06 |
| A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) MK-4716, Pembrolizumab, Cetuximab - Malignant Neoplasm | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-12-16 | 2026-10-30 |
| Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers CD-001 - Malignant Neoplasm, Head &Amp; Neck Cancer | Phase 1 | Not yet recruiting | West China Hospital | 9 | 2025-08-10 | 2025-08-03 |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) Patritumab Deruxtecan - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 50 | 2025-05-26 | 2026-10-06 |
| A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) MK-4700, Pembrolizumab - Malignant Neoplasm | Phase 1 | Completed | Merck Sharp & Dohme LLC | 5 | 2025-04-23 | 2026-03-16 |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) MK-3120 - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 270 | 2025-03-25 | 2026-10-28 |
| A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation TSN1611 - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Tyligand Pharmaceuticals (Suzhou) Limited | 440 | 2024-04-29 | 2026-04-24 |
| NV-001 in the Treatment of Advanced Solid Tumors NV-001 - Malignant Neoplasm | Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2023-12-01 | 2025-02-12 |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents OR502, Cemiplimab - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | OncoResponse, Inc. | 168 | 2023-10-24 | 2025-01-07 |
| NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma NBM-BMX Capsule, Temozolomide, Standard radiotherapy - Malignant Neoplasm, Malignant Neoplasm of Brain | Phase 1 / Phase 2 | Recruiting | Novelwise Pharmaceutical Corporation | 79 | 2023-08-11 | 2026-04-29 |
| TSN084 Treating Patients With Advanced Malignant Tumors TSN084 - Malignant Neoplasm | Phase 1 | Unknown | Tyligand Bioscience (Shanghai) Limited | 114 | 2022-07-20 | 2024-07-29 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors HMBD-002, Pembrolizumab - Cancer, Tumor, Solid | Phase 1 | Completed | Hummingbird Bioscience | 48 | 2022-02-28 | 2025-10-16 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents OR2805, Cemiplimab, Docetaxel - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Unknown | OncoResponse, Inc. | 172 | 2021-09-09 | 2023-11-02 |
| PM8002 in the Treatment of Patients With Advanced Solid Tumors PM8002 - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Biotheus Inc. | 380 | 2021-03-09 | 2024-12-05 |
| A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer NBM-BMX softgel capsules - Malignant Neoplasm | Phase 1 | Completed | NatureWise Biotech & Medicals Corporation | 21 | 2018-12-28 | 2023-08-15 |
| HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Chimeric Antigen Receptor T-Cell Therapy - Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2018-11-27 | 2026-08-12 |
| A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer NBM-BMX softgel capsules - Malignant Neoplasm | Phase 1 | Completed | NatureWise Biotech & Medicals Corporation | 33 | 2018-10-16 | 2022-04-13 |
Showing 20 of 34. Sign in to see all of them.
Neoplasms (34) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (4) · Breast Neoplasms (3) · Melanoma (3) · Brain Neoplasms (2) · Carcinoma, Transitional Cell (2) · Congenital Abnormalities (2) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Burkitt Lymphoma (1) · Carcinoma, Embryonal (1) · Carcinoma, Merkel Cell (1)
Neoplasms by Site (10) · Neoplasms by Histologic Type (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Pathological Conditions, Signs and Symptoms (6) · Breast Diseases (5) · Bronchial Neoplasms (5) · Carcinoma (5) · Carcinoma, Bronchogenic (5) · Hemic and Lymphatic Diseases (5) · Lung Diseases (5) · Lung Neoplasms (5)
pembrolizumab (4) · Cetuximab (2) · Sirolimus (2) · cemiplimab (2) · temsirolimus (2) · Adrenal Cortex Hormones (1) · Bevacizumab (1) · Bortezomib (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Chloroquine (1) · Curcumin (1) · Cytarabine (1) · Dexamethasone (1) · Disulfides (1)
Merck Sharp & Dohme LLC (8) · National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (2) · NatureWise Biotech & Medicals Corporation (2) · OncoResponse, Inc. (2) · Biotheus Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · City of Hope Medical Center (1) · Emory University (1) · Hummingbird Bioscience (1) · Mayo Clinic (1) · Novelwise Pharmaceutical Corporation (1) · OHSU Knight Cancer Institute (1) · Stanford University (1) · Tyligand Bioscience (Shanghai) Limited (1)
United States (26) · Israel (6) · China (5) · Canada (4) · South Korea (4) · Spain (4) · Taiwan (4) · Australia (3) · Chile (3) · France (3) · Japan (3) · Netherlands (3) · Belgium (2) · Czechia (2) · Denmark (2)
Sarina A Piha-Paul (2) · Afshin Dowlati (1) · Aminah Jatoi, M.D. (1) · Anthony W. Tolcher, M.D. (1) · Aung Naing (1) · Cindy Li (1) · David Kooby, MD (1) · Ewa Carrier (1) · Ian Robey, PhD (1) · Jana L Portnow (1) · Jerry J Jaboin (1) · Jie Wang, MD, PhD (1) · Judith Karp (1) · Manish Sharma (1)
PMID 15240677, PMID 18276844, PMID 18974373, PMID 21239698, PMID 22394984, PMID 22658127, PMID 23160470, PMID 24668327, PMID 26688544, PMID 27226436, PMID 27435312, PMID 28397821, PMID 29319049, PMID 29634946, PMID 29802087, PMID 29924973, PMID 37311055, PMID 38572751, PMID 41389341
2025 (3), U01CA062487 (3), U01CA062491 (3), U01CA062505 (2), U01CA069853 (2), U01CA070095 (2), P30CA014599 (1), P30CA016672 (1), P30CA069533 (1), P30CA124435 (1), R01CA093891 (1), U01CA062461 (1), U01CA062502 (1), U01CA069852 (1), U01CA099168 (1)